Identification of a novel fully human anti-toxic shock syndrome toxin (TSST)-1 single-chain variable fragment antibody averting TSST-1-induced mitogenesis and cytokine secretion

BMC Biotechnol. 2022 Oct 28;22(1):31. doi: 10.1186/s12896-022-00760-8.

Abstract

Background: Staphylococcal superantigens are virulence factors that help the pathogen escape the immune system and develop an infection. Toxic shock syndrome toxin (TSST)-1 is one of the most studied superantigens whose role in toxic shock syndrome and some particular disorders have been demonstrated. Inhibiting TSST-1 production with antibiotics and targeting TSST-1 with monoclonal antibodies might be one of the best strategies to prevent TSST-1-induced cytokines storm followed by lethality.

Results: A novel single-chain variable fragment (scFv), MS473, against TSST-1 was identified by selecting an scFv phage library on the TSST-1 protein. The MS473 scFv showed high affinity and specificity for TSST-1. Moreover, MS473 could significantly prevent TSST-1-induced mitogenicity (the IC50 value: 1.5 µM) and cytokine production.

Conclusion: Using traditional antibiotics with an anti-TSST-1 scFv as a safe and effective agent leads to deleting the infection source and preventing the detrimental effects of the toxin disseminated into the whole body.

Keywords: Autoimmune diseases; Single-chain variable fragment; Staphylococcus aureus; Superantigen; Toxic shock syndrome; Toxic shock syndrome toxin-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Cytokines / metabolism
  • Enterotoxins
  • Humans
  • Single-Chain Antibodies* / metabolism
  • Single-Chain Antibodies* / pharmacology
  • Staphylococcus aureus
  • Superantigens / metabolism
  • Superantigens / pharmacology

Substances

  • Single-Chain Antibodies
  • Superantigens
  • Enterotoxins
  • Cytokines
  • Anti-Bacterial Agents